Real-world data on epcoritamab for tough-to-treat lymphoma
Disease control
Ongoing
This study tracks how well the drug epcoritamab works for 150 adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have already tried at least two other treatments. Researchers will measure tumor shrinkage and side effects in everyday medical practice, not…
Sponsor: Andrés José Maria Ferreri • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC